A case series of diabetic ketoacidosis associated with SGLT2 inhibitors

IF 0.5 Q4 ENDOCRINOLOGY & METABOLISM

Practical Diabetes Pub Date : 2023-01-01 DOI:10.1002/pdi.2455

S. Zac-Varghese, S. Mathew, Daniel Go, P. Winocour

引用次数: 1

Abstract

Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) are increasingly initiated as treatment for type 2 diabetes due to favourable cardiorenal characteristics. However, studies have identified an increased risk of diabetic ketoacidosis (DKA).

查看原文本刊更多论文

与SGLT2抑制剂相关的糖尿病酮症酸中毒病例系列

钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)由于其良好的心肾特性，越来越多地被用作2型糖尿病的治疗。然而，研究已经确定糖尿病酮症酸中毒(DKA)的风险增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Practical Diabetes ENDOCRINOLOGY & METABOLISM-

CiteScore

1.10

自引率

16.70%

发文量

期刊介绍： Practical Diabetes concerns itself with all aspects of the worldwide clinical science and practice of diabetes medicine. The journal recognises the importance of each member of the healthcare team in the delivery of diabetes care, and reflects this diversity of professional interest in its editorial contents. The Editors welcome original papers, case reports, practice points, audit articles and letters on any aspect of clinical diabetes care from any part of the world. The journal also publishes commissioned leaders, review articles and educational and training series, for which an honorarium normally is paid. All articles submitted to Practical Diabetes are independently peer reviewed. They must not have been published or be under submission currently elsewhere. Enquiries from prospective authors are welcomed and the Editors will be pleased, if asked, to advise on preparation and submission of articles. All articles and enquiries should be directed to the Editors at the publishing address below. The journal is published nine times a year, and currently the average waiting time for acceptance of articles is eight weeks, and for subsequent publication sixteen weeks. Practical Diabetes is independent of any commercial or vested interest.